ARGX
argenx NV ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$50.40B
P/E Ratio
35.86
EPS
$22.49
Beta
-0.06
52W High
$934.62
52W Low
$510.06
50-Day MA
$769.96
200-Day MA
$794.48
Dividend Yield
—
Profit Margin
31.40%
Forward P/E
30.21
PEG Ratio
1.34
About argenx NV ADR
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Fundamentals
| Revenue (TTM) | $4.74B |
| Gross Profit (TTM) | $2.76B |
| EBITDA | $1.32B |
| Operating Margin | 30.00% |
| Return on Equity | 20.20% |
| Return on Assets | 8.86% |
| Revenue/Share (TTM) | $3.08 |
| Book Value | $4.73 |
| Price-to-Book | 6.84 |
| Price-to-Sales (TTM) | 10.63 |
| EV/Revenue | 9.92 |
| EV/EBITDA | 30.70 |
| Quarterly Earnings Growth (YoY) | 114.00% |
| Quarterly Revenue Growth (YoY) | 62.60% |
| Shares Outstanding | $62.19M |
| Float | $61.96M |
| % Insiders | 0.00% |
| % Institutions | 47.45% |
Historical Volatility
HV 10-Day
37.35%
HV 20-Day
32.13%
HV 30-Day
31.63%
HV 60-Day
30.73%
HV Rank
71.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($1023.39 target)
6
Strong Buy15
Buy3
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026